

Remarks/Arguments

Claims 1, 3, 8, 9, 11, 16 to 18 and 20 to 22 are presently pending. Claims 2, 4 to 7, 10, 12 to 15, 19, 20 and 22 are canceled, without prejudice. No new matter has been added.

Applicants reserve the right to pursue subject matter that remains after the prosecution of the present application in a future continuing patent application, for example, a division.

Applicants thank Examiner Chang for the telephone interview of January 10, 2010.

Claims 20 and 22 are canceled herewith as discussed. As further discussed, applicants respectfully request rejoinder of allowable claim 21 in accordance with MPEP § 821.04.

Conclusion

It is respectfully submitted that all of the claims are in condition for allowance. Early action to that end is respectfully requested. The Examiner is hereby invited to contact the undersigned attorney by telephone if there are any questions concerning this amendment or application.

The Commissioner is hereby authorized to charge any fees required to Deposit Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

/Cozette M. McAvoy/

Cozette M. McAvoy
Attorney for Applicant
Reg. No. 60,457

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
(862) 778-9273

Date: January 10, 2011